Sulfur hexafluoride

Drug Profile

Sulfur hexafluoride

Alternative Names: BRI; E-7210; Lumason; SonoVue; sulfur hexafluoride lipid-type A microspheres; Sulphur hexafluoride

Latest Information Update: 11 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bracco
  • Developer Bracco; Eisai Co Ltd
  • Class Contrast media; Fluorides; Inorganic sulfur compounds; Small molecules
  • Mechanism of Action Ultrasonography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cerebrovascular disorders
  • Registered Cardiovascular disorders; Liver disorders; Vesicoureteral reflux
  • Phase III Congenital heart defects; Coronary artery disease

Most Recent Events

  • 22 Jun 2017 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of sulfur hexafluoride for Vesiculoreteral reflux (Diagnosis, In neonates, In infants, In children, In adolsecents) in European Union (Intravesicular)
  • 21 Jun 2017 Preregistration for Vesicoureteral reflux (Diagnosis, In neonates, In infants, In children, In adolescents) in European Union (Intravesicular) before June 2017
  • 12 Jan 2017 Registered for Vesicoureteral reflux (Diagnosis, In children, In infants, In neonates, In adolescents) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top